RMAT designation for Yescarta in first-line high-risk LBCL

3 October 2024

The US Food and Drug Administration (FDA) has granted the Gilead Sciences (Nasdaq: GILD) subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL).

Suitable patients are identified through a positive positron emission tomography (PET) scan after two cycles of first-line chemoimmunotherapy. High-risk LBCL is a disease characterized by an aggressive course, early and frequent relapses, and low long-term survival rates. 

Since Yescarta was first approved as third-line plus treatment for adult patients with LBCL in 2017, followed by approval as second-line treatment in 2022, Kite has been focused on bringing the curative potential of CAR T-cell therapy as early in patients’ treatment course as possible. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology